Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)
TLSATiziana Life SciencesCatalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for Intranasal Foralumab (anti-CD3 mAb) in Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). The expected timing is based on the latest available company guidance and may change.
12/4/24- Expands Ph2 trial. 2/18/25- Announced dosing of add'l 4 patients. 3/25/25- Announced dosing at Yale. 4/2/25- Commenced dosing at JHU. 6/13/25- Dosing on multiple site commenced. 9/24/25- Poster presentation at ECTRIMS '25. 12/12/25:- na-SPMS EA program has 14 patients with stable or improved disease; Phase 2a trial ongoing. 02/25/26:- EA biomarker data from NCT06802328; Phase 2a trial NCT06292923 topline expected H1 2026. 05/14/26:- EA program NCT06802328 showed stability or improvement within 6 months in 14 patients. Ph2a topline H1 2026. 05/19/26:- NCT06802328 data through Mar 2026: 14 patients stable/improved; no new safety signals. Ph2a NCT06292923 ongoing. 05/21/26:- Enrollment completed in INFORM-MS Ph2a (NCT06292923); topline Late Q3 2026; ACTRIMS/ECTRIMS Oct 2026. 06/25/26:- Last patient received first dose in INFORM-MS Ph2a. Topline late Q3/early Q4 2026; ACTRIMS/ECTRIMS Oct 2026.
Verification
Confirm timing and program details against the company announcement or filing.